Member Info for Sunningdale1

Refers to 'sleeping giant' Hvivo - we picked up some £60m of assets for £10m.

Cathal is the definitely the man with the plan for the ORPH and HVO merger, he will have done homework - and besides they picked it up for a song. Once the merger goes through, Trevor will most likely only be involved at an operational level, but Cathal will be at the helm as he has the big picture, plus £2 mill of his own money in the pot too.

Don't think it will be boring at Open Orphan for much longer once Cathal gets HVO integrated.

Look Trevor has pushed HVO as hard as he can, but Cathal is the man with the plan here. Once the merger goes through, Trevor will be involved, probably at an operational level, but Cathal will be at the helm as he has the big picture and £2 mill of his own money in the pot too.

Who's expecting a big 2020? Cathal Friel has delivered as promised with the all share merger with hVIVO (HVO). Seeing as HVO was trading at 30p at the start of the year, 2.47 ORPH shares for for each HVO share at 15.6p is great value. This follows partnerships with biopharma giant Ipsen Group and Venn’s deal with Carna Bioscience, and will leverage up and commercialise HVO’s sb through the Open Orphan health data platform.

At 5.6p this still values ORPH at just £14m - combine in HVO at £11m plus the preferred partnership agreements and ORPH is set for a big 2020 imo.

"Closing at just £0.66GBX on Black Friday ECR looks a bargain Cyber Monday deal for investors seeking to capitalise on a bullish gold market within a world-class mining region in 2020."

http://branduk.net/ecr-minerals-ecr-cyber-monday-deal-buy-now-whilst-prices-are-low/

IMM one I'm certainly watching. Open Orphan (ORPH) my main focus currently - backing it to deliver the goods in 2020 . News flow has been consistent and positive. Last month, Venn Life Sciences, which is part of the ORPH group has been selected as the preferred partner for pharma Ipsen Group's Data Management and Biostatistics. The preferred vendor structure will last for a 3-year period. Ipsen had sales in excess of €2.2 billion last year.

CEO Cathal Friel discusses in recent podcast hxxps://total-market-solutions.com/2019/11/13/open-orphan-news/

This partnership has already delivered substantial revenues for the Open Orphan group and positions the business as an integrated drug development partner for Biopharma companies in Europe such as Ipsen.

Venn have also signed a contract with Carna Bioscience for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for the Company over the next 12months. Carna is a Japanese company developing innovative treatments against cancer and immune disorders.

Finances are strong! November delivered some more big news! Venn Life Sciences, which is part of the ORPH group has been selected as the preferred partner for pharma heavy weights Ipsen’s Data Management and Biostatistics. The preferred vendor structure will last for a 3-year period. Ipsen had sales in excess of €2.2 billion last year.

CEO Cathal Friel discusses in recent podcast hxxps://total-market-solutions.com/2019/11/13/open-orphan-news/

This partnership has already delivered substantial revenues for the Open Orphan group and positions the business as an integrated drug development partner for Biopharma companies in Europe such as Ipsen.

Venn have also signed a contract with Carna Bioscience for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for the Company over the next 12months. Carna is a Japanese company developing innovative treatments against cancer and immune disorders.

For those interested in my previous post on Open Orphan (ORPH), November delivered some big news! Venn Life Sciences, which is part of the ORPH group has been selected as the preferred partner for pharma heavy weights Ipsen’s Data Management and Biostatistics. The preferred vendor structure will last for a 3-year period. Ipsen had sales in excess of €2.2 billion last year.

CEO Cathal Friel discusses in recent podcast hxxps://total-market-solutions.com/2019/11/13/open-orphan-news/

This partnership has already delivered substantial revenues for the Open Orphan group and positions the business as an integrated drug development partner for Biopharma companies in Europe such as Ipsen.

Venn have also signed a contract with Carna Bioscience for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for the Company over the next 12months. Carna is a Japanese company developing innovative treatments against cancer and immune disorders.

For those interested in my previous post on Open Orphan (ORPH), November delivered some big news! Venn Life Sciences, which is part of the ORPH group has been selected as the preferred partner for pharma heavy weights Ipsen’s Data Management and Biostatistics. The preferred vendor structure will last for a 3-year period. Ipsen had sales in excess of €2.2 billion last year.

CEO Cathal Friel discusses in recent podcast hxxps://total-market-solutions.com/2019/11/13/open-orphan-news/

This partnership has already delivered substantial revenues for the Open Orphan group and positions the business as an integrated drug development partner for Biopharma companies in Europe such as Ipsen.

Venn have also signed a contract with Carna Bioscience for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for the Company over the next 12months. Carna is a Japanese company developing innovative treatments against cancer and immune disorders.

Great bounce back over the last 5 days. For those interested in other growing Pharma stocks, Maurice Treacy, CCO of Open Orphan #ORPH reveals they have signed five pharmaceutical and biotechnology companies as early adopters of its Genomic Health DataBANK platform on the Vox Podcast.

The interview starts at 10 minutes.

https://audioboom.com/posts/7433540-nuformix-open-orphan-zoetic-international-and-live-company-group

For those interested in other growing Pharma stocks, Maurice Treacy, CCO of Open Orphan #ORPH reveals they have signed five pharmaceutical and biotechnology companies as early adopters of its Genomic Health DataBANK platform on the Vox Podcast.

The interview starts at 10 minutes.

https://audioboom.com/posts/7433540-nuformix-open-orphan-zoetic-international-and-live-company-group

Ergomed a stock that just keeps on giving - my best buy for 2019. Let's hope for a strong finish to the year.

For those interested in other growing Pharma stocks, big news this week from Open Orphan! Venn Life Sciences, which is part of the ORPH group has been selected as the preferred partner for pharma heavy weights Ipsen Group’s ( Data Management and Biostatistics. The preferred vendor structure will last for a 3-year period. Ipsen had sales in excess of €2.2 billion last year.

This partnership has already delivered substantial revenues for the Open Orphan group and positions the business as an integrated drug development partner for Biopharma companies in Europe such as Ipsen.

This partnership is the first of many steps to make Venn profitable and deliver a re-rating of the business to be in line with the wider sector.

CEO Cathal Friel summaries the significance of the agreement in 2 minute video below. https://www.brrmedia.co.uk/broadcasts-embed/5dc99abe34a3cf1389e844e9/?open-orphan-rns&popup=true

Good to see OXB back rising today. For those interested in other growing Pharma stocks, big news this week from Open Orphan! Venn Life Sciences, which is part of the ORPH group has been selected as the preferred partner for pharma heavy weights Ipsen Group’s ( Data Management and Biostatistics. The preferred vendor structure will last for a 3-year period. Ipsen had sales in excess of €2.2 billion last year.

This partnership has already delivered substantial revenues for the Open Orphan group and positions the business as an integrated drug development partner for Biopharma companies in Europe such as Ipsen.

This partnership is the first of many steps to make Venn profitable and deliver a re-rating of the business to be in line with the wider sector.

CEO Cathal Friel summaries the significance of the agreement in 2 minute video below. https://www.brrmedia.co.uk/broadcasts-embed/5dc99abe34a3cf1389e844e9/?open-orphan-rns&popup=true

"For those interested in my previous post on Open Orphan - big news this week as Venn Life Sciences, which is part of the ORPH group has been selected as the preferred partner for pharma heavy weights Ipsen Group’s ( Data Management and Biostatistics. The preferred vendor structure will last for a 3-year period. Ipsen had sales in excess of €2.2 billion last year.

This partnership has already delivered substantial revenues for the Open Orphan group and positions the business as an integrated drug development partner for Biopharma companies in Europe such as Ipsen. It is the first of many steps to make Venn profitable and deliver a re-rating of the business to be in line with the wider sector.

CEO Cathal Friel summaries the significance of the agreement in 2 minute video below. https://www.brrmedia.co.uk/broadcasts-embed/5dc99abe34a3cf1389e844e9/?open-orphan-rns&popup=true"

For those interested in my previous post, big news this week from Open Orphan! Venn Life Sciences, which is part of the ORPH group has been selected as the preferred partner for pharma heavy weights Ipsen Group’s ( Data Management and Biostatistics. The preferred vendor structure will last for a 3-year period. Ipsen had sales in excess of €2.2 billion last year.

This partnership has already delivered substantial revenues for the Open Orphan group and positions the business as an integrated drug development partner for Biopharma companies in Europe such as Ipsen.

This partnership is the first of many steps to make Venn profitable and deliver a re-rating of the business to be in line with the wider sector.

CEO Cathal Friel summaries the significance of the agreement in 2 minute video below. https://www.brrmedia.co.uk/broadcasts-embed/5dc99abe34a3cf1389e844e9/?open-orphan-rns&popup=true

For those that were interested in my post on ORPH. Big news this week as Venn Life Sciences, which is part of the ORPH group has been selected as the preferred partner for pharma heavy weights Ipsen Group’s ( Data Management and Biostatistics. The preferred vendor structure will last for a 3-year period. Ipsen had sales in excess of €2.2 billion last year.
This partnership has already delivered substantial revenues for the Open Orphan group and positions the business as an integrated drug development partner for Biopharma companies in Europe such as Ipsen.
CEO Cathal Friel commented:
“When we completed the reverse takeover of Venn earlier this summer we promised shareholders that one of our key objectives would be to transform Venn into a profitable pharma services company. This partnership is the first of many steps to make Venn profitable and deliver a re-rating of the business to be in line with the wider sector. I look forward to announcing more positive news in due course.”
CEO Cathal Friel ensures this is not an exclusive offer but Venn have more customers lined up for the coming weeks in recent podcast hxxps://total-market-solutions.com/2019/11/13/open-orphan-news/

For those that were interested in my previous message on Open Orph (no worries if you're not) ORPH have very recently signed an agreement with Empiric Logic, a leading managed software service company. The Collaboration is the final stage in the completion of their Genomic Health Data platform and will speed up its launch.

Maurice Treacy highlights the significant value of the genomic health database in a presentation just before the announcement. Huge potential upside here. -

"When I talked about the 10,000 data records we hope to collect or corral in our database, each one of those per patient is valued roughly, based on these precedents, at about 5000. So the nominal value of that database is about 50 million.

That's just assuming a linear access fee. We hope there will be multiple pharma companies looking at this data at the same time."

https://www.youtube.com/watch?v=XrT6SBVa5F0 (16:36 onwards)

For more info Maurice Treacy is holding a live webinar tomorrow at 19:00 (UK time) https://vtm.clickmeeting.com/orph"

For those that were interested in my post on Open Orph (no worries if you're not) the companies CCO Maurice Treacy is holding a live webinar tomorrow 30th at 19:00 (UK time) https://vtm.clickmeeting.com/orph

The company has a four pronged strategy including a European health data collection platform - with patient clinical and genomic data. For measure GSK recently valued an Alzheimers neurologival disorder database for £300m so big money business. CCO Maurice Treacy explains on proactive https://www.youtube.com/watch?v=eFvPcwjL-m4

ORPH recently signed an agreement with Empiric Logic, a leading managed software service company. The Collaboration is the final stage in the completion of their Genomic Health Data platform and will speed up its launch.

For those that were interested in my previous message on Open Orph (no worries if you're not) ORPH have very recently signed an agreement with Empiric Logic, a leading managed software service company. The Collaboration is the final stage in the completion of their Genomic Health Data platform and will speed up its launch.

Maurice Treacy highlights the significant value of the genomic health database in a presentation just before the announcement. Huge potential upside here. -

"When I talked about the 10,000 data records we hope to collect or corral in our database, each one of those per patient is valued roughly, based on these precedents, at about 5000. So the nominal value of that database is about 50 million.

That's just assuming a linear access fee. We hope there will be multiple pharma companies looking at this data at the same time."

https://www.youtube.com/watch?v=XrT6SBVa5F0 (16:36 onwards)

For more info Maurice Treacy is holding a live webinar tomorrow at 19:00 (UK time) https://vtm.clickmeeting.com/orph"